Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- (-) Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 66 Results
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study
Researchers conducted cross-framework comparisons of multiple myeloma assessments using four value assessment frameworks and examined the consistency of findings across three case studies.
Why Value Framework Assessments Arrive at Different Conclusions
New peer-reviewed research from the National Pharmaceutical Council (NPC) found inconsistencies in how four value frameworks assessed multiple myeloma treatments.
National Eczema Association Weighs In on Value Frameworks
NPC President Dan Leonard recently sat down for a conversation with Julie Block, President and CEO of the National Eczema Association, to discuss atopic dermatitis (AD) and value assessment…
NPC Outlines Needed Improvements to ICER's Revised Value Assessment Framework
NPC submitted comments to the Institute for Clinical and Economic Review (ICER), offering constructive suggestions on ways to further improve its revised value assessment framework.
Including the Patient’s Perspective in Valuing Treatments for Arthritis
NPC President Dan Leonard sat down for a Q&A session with Sandie Preiss, Vice President for Advocacy and Access at the Arthritis Foundation, to discuss how the value of treatments for arthritis…
Workshop Looks “Under the Hood” of Value Assessment Frameworks
During the Feb. 27 interactive workshop, “Understanding the Strengths and Limitations of Value Assessment Frameworks,” hosted by the National Pharmaceutical Council and PhRMA, health care…
Value Assessment Frameworks: Are They Up To The Challenge?
In this article published on the Health Affairs Blog, NPC researchers Dr. Robert Dubois and Kimberly Westrich ask: Are value assessment frameworks ready to compare the health and economic impacts of…
NPC President Dan Leonard Offers Perspectives on Health Reform
In a commentary recently published in The American Journal of Pharmacy Benefits, NPC President Dan Leonard offered 10 key considerations for stakeholders as they navigate health reform discussions.
Comparison of Value Framework Assessments for Multiple Myeloma
In this NPC-funded study conducted by the Lewin Group, four existing value assessment frameworks were compared head to head to understand how each framework would approach the same condition,…
NPC President Dan Leonard Speaks on Value Frameworks at BioNJ
As our health care system shifts from a focus on volume to value, a key question emerges: Who gets to define value? National Pharmaceutical Council (NPC) President Dan Leonard and other health…
Assessing Value: Promise and Pitfalls Conference Summary Report
At NPC's conference, Assessing Value: Promise and Pitfalls, top experts in their fields united to discuss value assessment as it impacts payers, patients, providers and pharmaceutical innovators.
Comparison of Value Assessment Frameworks Using the National Pharmaceutical Council’s Guiding Practices for Patient-Centered Value Assessment
NPC worked with The Lewin Group to conduct an independent analysis of the extent to which five major value assessment frameworks address or align with NPC’s Guiding Practices for Patient-Centered…
Current Landscape: Value Assessment Frameworks
This paper builds on Neumann and Cohen's informative comparison of value assessment frameworks by carrying the assessment further and providing specific detailed observations. It delves deeper into…
Guiding Practices for Patient-Centered Value Assessment
In 2016, NP developed Guiding Practices for Patient-Centered Value Assessment that included 28 specific elements, which are broken out into six key aspects of value assessments: the assessment…
Translating Comparative Effectiveness Research into Medicaid Payment Policy: Views from Medical and Pharmacy Directors
NPC supported a survey of Medicaid medical and pharmacy directors to better understand how policy makers in the state Medicaid programs view comparative effectiveness research (CER) and how they use…
Exploration of Heterogeneity in Distributed Research Network Drug Safety Analyses
Distributed data network drug safety analyses are difficult to interpret in the face of heterogeneity, or individual treatment effects.
Consumer-Directed Health Plans: Pharmacy Benefits & "Better Practices"
The research was intended to identify the current landscape and best practice approaches for consumer-directed health plans and pharmacy benefits, as well as understand the health and economic impact…
Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design
Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications.
The Good, the Bad, and the Different: A Primer on Aspects of Heterogeneity of Treatment Effects
The concept of heterogeneity is explained and further explored via four articles published in the June 2014 issue of the Journal of Managed Care & Specialty Pharmacy: The Good, the Bad, and the…
The Emerging Relevance of Heterogeneity of Treatment Effect in Clinical Care: A Study Using Stage IV Prostate Cancer as a Model
Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react differently to treatments, the factors that impact treatment outcomes, including…